Trials / Unknown
UnknownNCT03889626
The Maintenance Treatment of Apatinib/Capecitabine Versus Observation in Advanced Gastric Cancer
A Phase III Study of Comparing the Maintenance Treatment of Apatinib, Capecitabine and Observation After First-line Therapy in Advanced Gastric Cancer
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 242 (estimated)
- Sponsor
- Fudan University · Academic / Other
- Sex
- All
- Age
- 18 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and tolerability of the maintenance treatment of Apatinib/Capecitabine after fluorouracil and platinum based first-line chemotherapy in advanced gastric cancer.
Detailed description
Up to now, whether maintenance therapy after first line treatment can bring survival benefits to patients with advanced gastric cancer is unknown, and let alone which drug is most suitable. Our study is designed to prove whether the maintenance treatment of Apatinib or Capecitabine are better than observation after fluorouracil/platinum based first-line chemotherapy in advanced gastric cancer
Conditions
- Stomach Neoplasms
- Gastrointestinal Neoplasms
- Stomach Diseases
- Digestive System Neoplasms
- Capecitabine
- Apatinib
- Neoplasms
- Molecular Mechanisms of Pharmacological Action
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Apatinib | Apatinib: 500mg qd po, q4w |
| DRUG | Capecitabine | Capecitabine: 1000mg/m2 bid po, d1-14, q3w |
Timeline
- Start date
- 2019-03-22
- Primary completion
- 2022-03-22
- Completion
- 2024-03-22
- First posted
- 2019-03-26
- Last updated
- 2019-03-26
Source: ClinicalTrials.gov record NCT03889626. Inclusion in this directory is not an endorsement.